Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Winclove Probiotics B.V. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
In this trial, the investigators aim to assess the effectiveness of a multispecies probiotic consisting of 2 strains of Bifidobacterium (B. bifidum W23, B. lactis W51) and 6 strains of Lactobacillus (L. acidophilus W37, L. acidophilus W55, L. paracasei W20, L. plantarum W62, L. rhamnosus W71, and L. salivarius W24) in reducing the risk of antibiotic-associated diarrhoea in a group of children undergoing antibiotic therapy for common infections.
Certain individual probiotic strains have been proven to be effective in reducing the risk of antibiotic-associated diarrhoea (AAD). However, the effects of using multispecies probiotics remain unclear. The investigators aim to assess the effectiveness of a specific multispecies probiotic preparation (Ecologic AAD Kids) in reducing the incidence of AAD in children.
In this trial, a total of 350 children aged 3 months to 18 years, undergoing antibiotic treatment, will be randomly allocated to receive either a multispecies probiotic consisting of 2 strains of Bifidobacterium (B. bifidum W23, B. lactis W51) and 6 strains of Lactobacillus (L. acidophilus W37, L. acidophilus W55, L. paracasei W20, L. plantarum W62, L. rhamnosus W71, and L. salivarius W24) at a total dose of 10^10 colony-forming units daily, or a placebo, from the first day of antibiotic treatment until 7 days after antibiotic cessation. The primary outcome measure will be the incidence of AAD, defined as ≥3 loose or watery stools (a score of A on the Amsterdam Infant Stool Scale for children younger than 1 year and a score of 5-7 on the Bristol Stool Form scale for children older than 1 year) in 24 hours, caused either by Clostridium difficile or of otherwise unexplained aetiology (after testing for common diarrhoeal pathogens), occurring during and/or up to 7 days after the end of the antibiotic therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multispecies probiotic group | Experimental | 175 participants. |
|
| Control group | Placebo Comparator | 175 participants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multispecies probiotic | Dietary Supplement | Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10^9 Colony Forming Units (CFU), twice daily, orally. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of antibiotic-associated diarrhea | Antibiotic-associated diarrhea will be defined as 3 or more loose or watery stools (a score of A on the Amsterdam Infant Stool Scale or 5-7 on the Bristol Stool Form scale) per day in a 24-hour period, caused by C. difficile infection or of otherwise unexplained aetiology after testing for common diarrhoeal pathogens (rotavirus, adenovirus, norovirus, Campylobacter spp., Salmonella spp., Shigella spp., and Yersinia spp.), occurring during the intervention period. | Up to 7th day after antibiotic cessation. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of antibiotic-associated diarrhea - alternative definition 1 | ≥3 loose or watery stools per day for a minimum of a 48-hour period caused by C. difficile infection or of otherwise unexplained aetiology. | Up to 7th day after antibiotic cessation. |
| Incidence of antibiotic-associated diarrhea - alternative definition 2 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jan Łukasik, MD | Department of Paediatrics, The Medical University of Warsaw, Poland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| OLVG location West | Amsterdam | 1061 | Netherlands | |||
| Amsterdam UMC, location VUmc |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38967929 | Derived | Dierikx TH, Malinowska AM, Lukasik J, Besseling-van der Vaart I, Belzer C, Szajewska H, de Meij TGJ; Multispecies Probiotic in AAD Study Group. Probiotics and Antibiotic-Induced Microbial Aberrations in Children: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2418129. doi: 10.1001/jamanetworkopen.2024.18129. | |
| 35727573 |
Not provided
Not provided
The data collected in the course of this study are available from the Principal Investigator upon reasonable request.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Other | Placebo identical in taste, smell and color to the multispecies probiotic. |
|
≥2 loose or watery stools per day for a minimum of a 24-hour period caused by C. difficile infection or of otherwise unexplained aetiology. |
| Up to 7th day after antibiotic cessation. |
| Incidence of diarrhea | ≥3 loose or watery stools per day for a minimum of 24 hours regardless of its aetiology. | Up to 7th day after antibiotic cessation. |
| Clostridium difficile-associated diarrhea | ≥3 loose or watery stools per day for a minimum of 24 hours caused by C. difficile confirmed by the presence of toxin-producing C. difficile in stools. | Up to 7th day after antibiotic cessation. |
| Duration of diarrhea | Defined as the time until the normalisation of stool consistency according to the Bristol Stoo Form (BSF) or Amsterdam Infant Stool Scale (AISS) - on BSF numbers 1, 2, 3 and 4; on AISS scale, letters B or C, and the presence of normal stools for 48 h. | Up to 7th day after antibiotic cessation. |
| Discontinuation of the antibiotic treatment due to severity of diarrhoea | Up to 7th day after antibiotic cessation. |
| Hospitalisation caused by diarrhoea | Up to 7th day after antibiotic cessation. |
| Need for intravenous rehydration | Up to 7th day after antibiotic cessation. |
| Adverse events | Up to 7th day after antibiotic cessation. |
| Amsterdam |
| 1081 HV |
| Netherlands |
| OLVG location East | Amsterdam | 1092 | Netherlands |
| Amsterdam UMC, location AMC | Amsterdam | 1105 | Netherlands |
| Department of Paediatrics, St. Hedwig of Silesia Hospital | Trzebnica | Silesian Voivodeship | 55-100 | Poland |
| Department of Paediatrics, The Medical University of Warsaw, Poland | Warsaw | 02-091 | Poland |
| Lukasik J, Dierikx T, Besseling-van der Vaart I, de Meij T, Szajewska H; Multispecies Probiotic in AAD Study Group. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatr. 2022 Sep 1;176(9):860-866. doi: 10.1001/jamapediatrics.2022.1973. |
| 29866789 | Derived | Lukasik J, Szajewska H. Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial. BMJ Open. 2018 Jun 4;8(5):e021214. doi: 10.1136/bmjopen-2017-021214. |